Literature DB >> 8593368

Surveillance of drug resistance for tuberculosis control: why and how?

P Chaulet1, F Boulahbal, J Grosset.   

Abstract

The resistance of Mycobacterium tuberculosis to antibiotics, which reflects the quality of the chemotherapy applied in the community, is one of the elements of epidemiological surveillance used in national tuberculosis programmes. Measurement of drug resistance poses problems for biologists in standardization of laboratory methods and quality control. The definition of rates of acquired and primary drug resistance also necessitates standardization in the methods used to collect information transmitted by clinicians. Finally, the significance of the rates calculated depends on the choice of the patients sample on which sensitivity tests have been performed. National surveys of drug resistance therefore require multidisciplinary participation in order to select the only useful indicators: rates of primary resistance and of acquired resistance. These indicators, gathered in representative groups of patients over a long period, are a measurement of the impact of modern chemotherapy regimens on bacterial ecology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593368     DOI: 10.1016/0962-8479(95)90523-5

Source DB:  PubMed          Journal:  Tuber Lung Dis        ISSN: 0962-8479


  7 in total

Review 1.  Epidemiology, control and treatment of multidrug-resistant tuberculosis.

Authors:  P Chaulet; M Raviglione; F Bustreo
Journal:  Drugs       Date:  1996       Impact factor: 9.546

2.  Use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant Mycobacterium tuberculosis.

Authors:  R N Mshana; G Tadesse; G Abate; H Miörner
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

3.  DRUG RESISTANT TUBERCULOSIS.

Authors:  S P Kalra; S C Tewari; R Jayaswal
Journal:  Med J Armed Forces India       Date:  2017-06-26

4.  Primary Drug-Resistance Pattern and Trend in Elderly Tuberculosis Patients in Shandong, China, from 2004 to 2019.

Authors:  Qiqi An; Wanmei Song; Jinyue Liu; Ningning Tao; Yao Liu; Qianyun Zhang; Tingting Xu; Shijin Li; Siqi Liu; Yifan Li; Chunbao Yu; Huaichen Li
Journal:  Infect Drug Resist       Date:  2020-11-13       Impact factor: 4.003

5.  Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide.

Authors:  Zhenling Cui; Jie Wang; Junmei Lu; Xiaochen Huang; Ruijuan Zheng; Zhongyi Hu
Journal:  J Clin Microbiol       Date:  2013-02-06       Impact factor: 5.948

6.  Strong decrease in streptomycin-resistance and absence of XDR 12 years after the Reorganization of the National Tuberculosis Control Program in the Central Region of Cameroon.

Authors:  Larissa Kamgue Sidze; Emmanuel Mouafo Tekwu; Christopher Kuaban; Jean-Paul Assam Assam; Jean-Claude Tedom; Sara Eyangoh; François-Xavier Fouda; Désiré Nolna; Francine Ntoumi; Matthias Frank; Véronique N Penlap Beng
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

7.  Multidrug-resistant tuberculosis in HIV-negative patients, Buenos Aires, Argentina.

Authors:  Domingo Palmero; Viviana Ritacco; Martha Ambroggi; Natiello Marcela; Lucía Barrera; Lilian Capone; Alicia Dambrosi; Martha di Lonardo; Nélida Isola; Susana Poggi; Marisa Vescovo; Eduardo Abbate
Journal:  Emerg Infect Dis       Date:  2003-08       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.